Equity Overview
Price & Market Data
Price: $5.13
Daily Change: +$0.06 / 1.17%
Range: $5.03 - $5.78
Market Cap: $81,841,456
Volume: 37,465
Performance Metrics
1 Week: 7.77%
1 Month: -35.87%
3 Months: -33.72%
6 Months: 7.32%
1 Year: -44.36%
YTD: 0.59%
Company Details
Employees: 32
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.